➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
McKinsey
Medtronic
Express Scripts
AstraZeneca

Last Updated: January 20, 2021

DrugPatentWatch Database Preview

Litigation Details for Lupin Atlantis Holdings SA v. Apotex Inc. (S.D.N.Y. 2011)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Lupin Atlantis Holdings SA v. Apotex Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Lupin Atlantis Holdings SA v. Apotex Inc. (S.D.N.Y. 2011)

Date Filed Document No. Description Snippet Link To Document
2011-06-08 22 Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,101,574; 7,863,331… CLOSED, PATENT U.S. District… Nature of Suit: 830 Patent … USDC/SD/NY, 11cv668 Cause: 35:271 Patent Infringement Plaintiff Lupin Atlantis Holdings …/18/2011 Ï3 Supplemental information for patent cases involving an Abbreviated New Drug Application External link to document
2011-06-15 23 U.S. Patent No. 7,101,574 (“the ’574 patent”) and U.S. Patent No. 7,863,331 (“the ’331 patent”) that… : In re FENOFIBRATE PATENT LITIGATION : No. 1:11-md-02241 (JSR) … Filed 06/15/11 Page 2 of 12 The ’574 patent has 34 claims, two of which are independent claims…derivative is between 5/1 and 15/1. The ’331 patent has 4 claims, of which claim 1 is the sole independent… Claim Terms of The ’574 Patent To Be Construed By The Court Claim External link to document
2011-06-21 25 ABBREVIATIONS ‟574 patent U.S. Patent No. 7,101,574331 patent U.S. Patent No. 7,863,331 … The ’331 Patent The ‟331 patent, a continuation-in-part of the ‟574 patent, claims a method…1999. The ‟331 patent claims priority to the ‟574 patent as well as the parent French Patent Application.…clauses in the ’574 patent and ’331 patent 1. The ’574 patent Disputed Terms of the… the ‟574 Patent ..................... 14 2. “Granules” in the ‟331 Patent .......... External link to document
2011-06-21 26 specifically disclosed in U.S. Patent No. 6,074,670 (“the ’670 patent” or “Stamm”). See Ex. 4, ’670 …same patent family as the ’574 patent.4 The ’331 patent’s specification repeats the ’574 patent specification…disputed terms in U.S. Patent No. 7,101,574 B1 (“the ’574 patent”) and U.S. Patent No. 7,863,331 B2 (“the… the ’574 patent is invalid, it is now using that same patent and the related ’331 patent to prevent … ’331 Patent. The ’331 patent was filed as a continuation-in-part of the ’574 patent and is, therefore External link to document
2011-06-21 27 ABBREVIATIONS ‟574 patent U.S. Patent No. 7,101,574331 patent U.S. Patent No. 7,863,331 … The ’331 Patent The ‟331 patent, a continuation-in-part of the ‟574 patent, claims a method…1999. The ‟331 patent claims priority to the ‟574 patent as well as the parent French Patent Application.…clauses in the ’574 patent and ’331 patent 1. The ’574 patent Disputed Terms of the… the ‟574 Patent ..................... 14 2. “Granules” in the ‟331 Patent .......... External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Moodys
McKesson
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.